Author name: Leonardo Arias

Calls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.

Strong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milvexian.

Regulators say the telehealth company illegally shared patient health data with advertisers and misled its customers. Hims & Hers hit back, calling the claims “baseless.”

Medtronic has backed CoreMap to address a critical unmet need in atrial fibrillation treatment.

Rocco De Bernardis, global president for Ottava, gets into the details of what makes the new robotic surgery system different from the competition and how the healthcare giant plans to roll it out.

Dr. Jaewon Ryu said he was stepping down to spend more time with his family. Risant is bringing out Dale Maxwell, a retired hospital executive, to serve as interim leader while it searches for a replacement.

With Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.

In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away.

Sanofi is going to “look very deeply” at its late-stage pipeline as part of a portfolio prioritization initiative, though new CEO Belén Garijo didn’t commit to shelving a specific number of assets.

As part of the collaboration, Johnson & Johnson will have an exclusive option to acquire Sail Biomedicines for an additional $2.58 billion.